Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.70 and traded as high as $9.00. Hemispherx BioPharma shares last traded at $6.70, with a volume of 7,639 shares.
Hemispherx BioPharma Stock Down 20.0%
The company has a 50 day simple moving average of $6.70 and a 200-day simple moving average of $6.70.
About Hemispherx BioPharma
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) is a U.S.-based biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of viral infections, cancers and immune system disorders. The company’s research centers on harnessing the body’s innate immune response to address diseases that currently lack broadly effective treatments.
Hemispherx’s principal commercial product is Alferon N Injection, an antiviral drug indicated for the treatment of external genital warts.
See Also
- Five stocks we like better than Hemispherx BioPharma
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
- If You Keep Cash In A U.S. Bank Account… Read This NOW
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
